Posts

With Voxzogo under pressure, BioMarin touts trial win in label expansion bid

on

BioMarin Suffers Another Blow to Rare Disease Portfolio in Phase 3 Flop

on

BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test

on

BioMarin Reports First Quarter 2026 Financial and Operating Results

on

BioMarin and Voxzogo: Recent Clinical Developments and Safety Information

on

BioMarin Posts Job Opening for Sr. Manager, Commercial IT Solutions Delivery – Data

on

BioMarin Veterans Launch Mendra Biotech with $82M for AI-Driven Rare Disease Drugs

on

BioMarin Veterans Launch Mendra Biotech with $82M for AI-Driven Rare Disease Drugs

on

BioMarin Announces $4.8 Billion Acquisition of Amicus Therapeutics for Rare Disease Portfolio Expansion

on

BioMarin Plans to Divest Hemophilia Gene Therapy Roctavian Amid Strategic Refocus

on

BioMarin Drops Preclinical PKU Drug Once Seen as Potential Palynziq Successor

on

BioMarin Acquires Inozyme Pharma for $270M, Gaining Phase 3 Rare Disease Therapy

on

BioMarin's R&D Chief Warns of Innovation Slowdown Amid NIH Funding Cuts

on